Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
HDAC Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
HDAC Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Histone deacetylases (HDAC) are a class of enzymes that remove acetyl groups from an N-acetyl lysine amino acid on both histone and non-histone proteins. HDACs allow histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones and DNA expression is regulated by acetylation and de-acetylation. HDAC's action is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases. HDAC involved biological functions including transcription, metabolism, oxidative stress, redox, protein degradation, and cell cycle among others. Histone deacetylases are expressed in different tumors; class I and II HDACs are general oncoproteins that interact with substrates and regulate gene expression to promote tumorigenesis and cancer development either individually or alongside co-repressors. The mechanism of action (MOA) of HDAC Inhibitor is that work by HDIs block HDAC enzyme activity by binding to the zinc ion in the catalytic site, which blocks substrate access to the site and histone deacetylase inhibitors exert their anti-tumour effects via the induction of expression changes of oncogenes or tumor suppressors. HDAC Inhibitors are used for the treatment of lymphoma, blood coagulation disorders, leukemia, sarcoma, hematologic diseases, Hodgkin disease, gastrointestinal diseases, multiple myeloma, vascular diseases, and breast neoplasm among others. Increased prevalence of sarcoma and lymphoma are the key drivers for the HDAC Inhibitor market. For instance, According to the World Health Organization 2023, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. Launch of newer products by the market players could seek opportunities that influence extensive research and development in HDAC inhibitors. For instance, Chipscreen Bioscience’s Epidaza (Chidamide) is used to treat relapsed or refractory peripheral T cell lymphoma (PTCL). Moreover, the development of novel molecules by key players are coming up to overcome challenges in therapy. For instance, Italfarmaco’s Givinostat (ITF2357) for the treatment of juvenile idiopathy is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for HDAC Inhibitor:
Drugs under the Pipeline for HDAC Inhibitor:
Clinical Activity and Developments of HDAC Inhibitor:
As of June 2023, more than 55 companies have approximately 42 molecules targeting 625 diseases. For these molecules, more than 296 clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials. For instance,
|
Molecule Name |
Number of Studies |
|
Zolinza (Vorinostat) |
285 |
|
Istodax (Romidepsin) |
106 |
|
Jingzhuda (Entinostat) |
74 |
|
Beleodaq (Belinostat) |
54 |
|
Givinostat (ITF2357) |
25 |
The molecules such as Epidaza (Chidamide) developed by Chipscreen Biosciences for the line of treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). 4SC’s Kinselby (Resminostat) is used to treat Cutaneous T-cell lymphoma (CTCL) a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). Moreover, Italfarmaco’s Givinostat (ITF2357) for the therapy of juvenile idiopathic arthritis, Duchenne muscular dystrophy, and Mundipharma’s Tinostamustine (EDO-S101) to improve drug access to DNA strands within cancer cells, break them, and counteract damage repair is under the clinical development.
Total revenues of Bristol Myers Squibb’s Istodax (Romidepsin) Before the megamerger, Celgene reported that Istodax sales declined 17% year-over-year in FY2018 to just USD 63 million in US, used for indication of treatment of cutaneous T-cell lymphoma (CTCL). Increase incidence of Lymphoma and other cancers Seems to create an opportunity for the future and burgeon the growth of the HDAC Inhibitor market. For instance, according to American Cancer Society 2023, About 80,550 people (44,880 males and 35,670 females) will be diagnosed with non-Hodgkin lymphoma (NHL). This includes both adults and children in the US and is expected to Create lucrative opportunity for HDAC Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Epidaza (Chidamide), Kinselby (Resminostat), and Istodax (Romidepsin) are the few FDA-approved PDE4 Inhibitor.
Total revenues of Bristol Myers squibb’s Istodax (Romidepsin) Before the megamerger, Celgene reported that Istodax sales declined 17% year-over-year in FY 2018 to just US$ 63 million in the US.
Major market players include Huya Bioscience, Secura Bio, 4SC, Astellas, and Bristol Myers Squibb are few leading market players.
Major Indications for HDAC Inhibitor are used to treat lymphoma, blood coagulation disorders, leukemia, sarcoma, hematologic diseases, and Hodgkin disease among others
There are a total of 38 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.